STOCKHOLM, Sweden--(BUSINESS WIRE)--A completed share issue by San Francisco based Epiphany Biosciences, Inc., Medivir’s (STO:MVIRB) licensing partner for the shingles project MIV-606 (also known as EPB-348), has led to Medivir obtaining shares in Epiphany corresponding to a 2 % ownership in the company.
